Recent Nanocarrier Approaches for Targeted Drug Delivery in Cancer Therapy

Author(s): Rohit Bhatia, Amit Sharma, R. K. Narang, Ravindra K. Rawal*

Journal Name: Current Molecular Pharmacology

Volume 14 , Issue 3 , 2021

Become EABM
Become Reviewer
Call for Editor


Cancer is one of the most serious health concerns in the 21st century whose prevalence is beyond boundaries and can affect any organ of the human body. The conventional chemotherapeutic treatment strategies lack specificity to tumors and are associated with toxic effects on the immune system and other organ systems. In the past decades, there has been continuous progress in the development of smart nanocarrier systems for target-specific delivery of drugs against a variety of tumors, including intracellular gene-specific targeting. These nanocarriers are able to recognize the tumor cells and deliver the therapeutic agent in fixed proportions, causing no or very less harm to healthy cells. Nanosystems have modified physicochemical properties, improved bioavailability, and long retention in blood, which enhances their potency. A huge number of nanocarrier based formulations have been developed and are in clinical trials. Nanocarrier systems include polymeric micelles, liposomes, dendrimers, carbon nanotubes, gold nanoparticles, etc. Recent advancements in nanocarrier systems include mesoporous silica nanoparticles (MSNs), metal organic frameworks, and quantum dots. In the present review, various nanocarrier based drug delivery systems, along with their applications in the management of cancer, have been described with special emphasis on MSNs.

Keywords: Nanocarriers, specificity, dendrimers, nanotubes, MSNs, quantum dots.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Page: [350 - 366]
Pages: 17
DOI: 10.2174/1874467213666200730114943
Price: $95

Article Metrics

PDF: 54